Xing Future Institute Launches: Empowering Ecosystems, Driving Continuous Evolution

On June 28, 2019, the Xing Weilai Institute, jointly established by Fosun and Fosun Pharma, officially launched at the Bund Finance Center in Shanghai. The Xing Weilai Institute is an investment and incubation platform focused on innovation and entrepreneurship in healthcare. Leveraging the extensive industrial resources of Fosun and Fosun Pharma in the medical and health sectors, it provides entrepreneurs in the broader health industry with an open learning platform through models such as “fund investment + incubation training + entrepreneurial services.”

From the launch of enrollment in April to the end of May, the 2019 Rocket Class of Star Future Institute recruited a total of 48 entrepreneurs in the healthcare sector. They came from over 20 countries and cities, including the United States, Japan, Hong Kong (China), Taiwan (China), Beijing, Shanghai, Suzhou, Wuxi, Wuhan, Chengdu, Shenzhen, Guangzhou, Qingdao, and Nanjing. Their business areas covered more than 20 medical specialties, with project stages ranging from growth-stage companies to listed firms. Among them, medical services, mobile health, and medical devices accounted for 38%, 24%, and 22%, respectively.

The curriculum system is structured around six core training modules, each adopting a “2+1” instructional model—comprising two days of intensive lectures followed by one day of site visits or workshops—with a total program duration of one year. It is reported that participating companies will gain access to Fosun’s three core resources, designed to support the growth of selected enterprises.

1. Top-tier Faculty: Leveraging the industrial backgrounds of Fosun and Fosun Pharma, we have invited leading global experts in healthcare and industry to provide entrepreneurs with practical incubation and acceleration services.

2. Industrial Synergy: Integrating Fosun’s industrial resources and management expertise—including those from Fosun Pharma, Fosun Property, Fosun-affiliated hospitals, Fosun Insurance, and Fosun Tourism Group—with the team to support entrepreneurs throughout their growth journey.

3. Project Investment: High-quality projects with strong synergy with Fosun may also receive investment from Star Future Capital, while other high-quality projects will attract attention from Fosun’s ecosystem funds and multiple top-tier investment institutions.

Chen Qiyu, Dean of Star Future Institute, Co-President of Fosun International, and Chairman of Fosun Pharma, stated that entrepreneurs, in addition to pursuing IPOs and higher valuations, are certainly committed to driving innovation. In particular, founders in the healthcare sector focus more on how to bring positive changes to society and the world. Fosun and the Star Future Institute aim to support such entrepreneurs and work together to advance human health.

As a venture capital firm under Fosun Group focused on early-stage investments in the broader healthcare sector, Star Future Capital has invested in nearly 20 projects and manages assets of approximately RMB 1 billion since its establishment in 2015. Its investment portfolio spans biotechnology, digital health, innovative medical devices, and frontier technologies.